Emerging role of FBXO22 in carcinogenesis

被引:31
作者
Cheng, Jiangting [1 ,2 ]
Lin, Min [3 ,4 ]
Chu, Man [3 ,4 ]
Gong, Longyuan [1 ,2 ]
Bi, Yanli [1 ,2 ]
Zhao, Yongchao [1 ,2 ]
机构
[1] Zhejiang Univ, Minist Publ Hlth, Affiliated Hosp 1, Key Lab Combined Multiorgan Transplantat,Sch Med, Hangzhou, Peoples R China
[2] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou, Peoples R China
[3] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China
[4] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
F-BOX PROTEINS; UBIQUITIN LIGASES; CELL-CYCLE; CANCER; EXPRESSION; MICRORNA155; PROGRESSION; CARCINOMA; INVASION; PATH;
D O I
10.1038/s41420-020-00303-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The F-box protein 22 (FBXO22), one of F-box proteins, has been identified to be critically involved in carcinogenesis. FBXO22 promotes proliferation in breast cancer and lung cancer, but suppresses migration and metastasis. FBXO22 exerts oncogenetic functions via promoting the ubiquitination and degradation of its substrates, including KDM4A, KDM4B, methylated p53, p21, KLF4, LKB1, Snail, CD147, Bach1, PTEN, and HDM2. FBXO22 is also regulated by several regulatory factors such as p53, miR-155, SNHG14, and circ_0006282. In this review, we summarize the regulatory factors and downstream targets of FBXO22 in cancers, discuss its functions in tumorigenesis, and further highlight the alteration of FBXO22 expression in a variety of human malignancies. Finally, we provide novel insights for future perspectives on targeting FBXO22 as a promising strategy for cancer therapy.
引用
收藏
页数:7
相关论文
共 51 条
[1]   SCFFBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis [J].
Bai, Jin ;
Wu, Kenneth ;
Cao, Meng-Han ;
Yang, Yingying ;
Pan, Yu ;
Liu, Hui ;
He, Yizhou ;
Itahana, Yoko ;
Huang, Lan ;
Zheng, Jun-Nian ;
Pan, Zhen-Qiang .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (24) :11754-11763
[2]   Cullin-RING ligases in regulation of autophagy [J].
Cui, Danrui ;
Xiong, Xiufang ;
Zhao, Yongchao .
CELL DIVISION, 2016, 11
[3]   Relationship Between Serum microRNA155 and Telomerase Expression in Hepatocellular Carcinoma [J].
Ezzat, Wafaa M. ;
Amr, Khalda Said ;
Raouf, Haiam Abdel ;
Elhosary, Yasser A. ;
Hegazy, Abdelfattah E. ;
Fahim, Hoda H. ;
Kamel, Refaat R. .
ARCHIVES OF MEDICAL RESEARCH, 2016, 47 (05) :349-355
[4]   FBXO22 degrades nuclear PTEN to promote tumorigenesis [J].
Ge, Meng-Kai ;
Zhang, Na ;
Xia, Li ;
Zhang, Cheng ;
Dong, Shuang-Shu ;
Li, Zhan-Ming ;
Ji, Yan ;
Zheng, Min-Hua ;
Sun, Jing ;
Chen, Guo-Qiang ;
Shen, Shao-Ming .
NATURE COMMUNICATIONS, 2020, 11 (01)
[5]   Kruppel-like factor 4 (KLF4): What we currently know [J].
Ghaleb, Amr M. ;
Yang, Vincent W. .
GENE, 2017, 611 :27-37
[6]   CD147: Regulator of Hyaluronan Signaling in Invasiveness and Chemoresistance [J].
Grass, G. Daniel ;
Dai, Lu ;
Qin, Zhiqiang ;
Parsons, Chris ;
Toole, Bryan P. .
HYALURONAN SIGNALING AND TURNOVER, 2014, 123 :351-373
[7]   FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis [J].
Guo, Feng ;
Liu, Jinjin ;
Han, Xiao ;
Zhang, Xuping ;
Lin, Tian ;
Wang, You ;
Bai, Jin ;
Han, Junqing .
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (03) :647-656
[8]   The post-translational modification, SUMOylation, and cancer (Review) [J].
Han, Zhi-Jian ;
Feng, Yan-Hu ;
Gu, Bao-Hong ;
Li, Yu-Min ;
Chen, Hao .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (04) :1081-1094
[9]   Circular RNA circ_0006282 Contributes to the Progression of Gastric Cancer by Sponging miR-155 to Upregulate the Expression of FBXO22 [J].
He, Yiren ;
Wang, Yinfeng ;
Liu, Liu ;
Liu, Shaojun ;
Liang, Lichuan ;
Chen, Yinan ;
Zhu, Zhiqiang .
ONCOTARGETS AND THERAPY, 2020, 13 :1001-1010
[10]   The intricate dance of post-translational modifications in the rhythm of life [J].
Hirano, Arisa ;
Fu, Ying-Hui ;
Ptacek, Louis J. .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2016, 23 (12) :1053-1060